Unity Biotechnology (NASDAQ:UBX) Posts Earnings Results, Beats Estimates By $0.02 EPS

Unity Biotechnology (NASDAQ:UBX) released its quarterly earnings results on Monday. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02, Zacks reports.

Unity Biotechnology Stock Down 5.0 %

Shares of NASDAQ:UBX traded down $0.06 during midday trading on Wednesday, hitting $1.15. 169,265 shares of the stock traded hands, compared to its average volume of 63,372. The stock has a market capitalization of $19.38 million, a PE ratio of -0.87 and a beta of 0.83. The business’s 50 day moving average is $1.44 and its two-hundred day moving average is $1.47. Unity Biotechnology has a one year low of $1.11 and a one year high of $2.26.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on UBX. Rodman & Renshaw began coverage on shares of Unity Biotechnology in a report on Thursday, August 22nd. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Unity Biotechnology in a report on Thursday, August 8th.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.